Oruka Therapeutics, Inc. (ORKA), a clinical-stage biotechnology company, announced that it will report Week 16 data from the ongoing EVERLAST-A Phase 2a trial of its lead investigational candidate ORKA-001, in moderate-to-severe plaque psoriasis on April 27, 2026, Monday.
Company Profile
Oruka Therapeutics develops monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its lead products include ORKA-001 for the treatment of psoriasis and ORKA-002 for the treatment of plaque psoriasis, psoriatic arthritis, and other conditions.
ORKA-001 is a novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19.
Trial Details
EVERLAST-A is a randomised, double-blind, placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients.
EVERLAST-A enrolled approximately 80 patients, randomised 3:1 to receive ORKA-001 or a matching placebo. The primary endpoint is PASI 100 at week 16.
PASI stands for Psoriasis Area and Severity Index, a scoring system doctors use to measure the intensity of psoriasis.
In addition, the company earlier reported having plans to provide longer-term data for ORKA-001, including week 28 for all patients and 52-week follow-up for a portion of the cohort in the second half of 2026.
Financial results
For the full year 2025, Oruka's net loss was $105.4 million, compared to $83.7 million in the prior year.
As of December 31, 2025, Oruka had cash, cash equivalents and marketable securities of $479.6 million.
ORKA has traded between $8.91 and $71.00 over the last year. The stock closed Friday's trade at $69.03, up 1.90%.
In the overnight market, ORKA is up 1.42%, at $70.01.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.